Meeting
2019 ASCO Annual Meeting
Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Authors
Jian-Ming Xu
Department of GI Oncology, the Fifth Medical Center, General Hospital of PLA, Beijing, China
Jian-Ming Xu , Rongrui Liu , Yi Ba , Da Jiang , Mingxia Wang , Yulong Zheng , Jia Wei , Yu-Xian Bai , Lizhu Lin , Jianping Xiong , Xixi Zhu , Chuanhua Zhao , Ru Jia , Yun Zhang , Jianzhi Liu , Gairong Zhang , Guangze Li , Quanren Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT 03026881
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4060)
DOI
10.1200/JCO.2019.37.15_suppl.4060
Abstract #
4060
Poster Bd #
165
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.
First Author: Michael Cecchini
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Identification of a subpopulation of patients with gastric cancer responsive to PARP inhibitors.
First Author: Simona Corso
Poster
2021 ASCO Annual Meeting
A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis.
First Author: Ying Cheng
Poster
2021 ASCO Annual Meeting
A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.
First Author: Seock-Ah Im